Here the list of events till year end:

1/ Q3 results. Nothing special expected. It will be good to have an update on cash and sales.

2/ Cetrorelix EU Efficacy trial results + update on registration strategy

3/ Perifosine Phase 3 in multiple myeloma initiated

4/ Perifosine update on metastatic colon and renal cancer development path

Next weeks for sure will be interesting.

Good luck to all,

Arycks